Fennec Pharmaceuticals Inc
General ticker "FENC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $163.6M
Fennec Pharmaceuticals Inc does not follow the US Stock Market performance with the rate: -33.5%.
Estimated limits based on current volatility of 3.0%: low 5.79$, high 6.15$
Factors to consider:
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [6.60$, 13.32$]
- 2024-12-30 to 2025-12-30 estimated range: [6.25$, 12.84$]
Financial Metrics affecting the FENC estimates:
- Negative: Non-GAAP EPS, $ of -0.61 <= 0.10
- Negative: Operating profit margin, % of -37.54 <= 1.03
- Negative: Operating cash flow per share per price, % of -6.32 <= 2.35
- Negative: negative Net income
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
Short-term FENC quotes
Long-term FENC plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $1.53MM | $21.25MM |
| Operating Expenses | $17.22MM | $24.12MM | $34.02MM |
| Operating Income | $-17.22MM | $-22.59MM | $-12.77MM |
| Non-Operating Income | $-0.12MM | $-1.12MM | $-3.27MM |
| Interest Expense | $0.13MM | $0.98MM | $3.39MM |
| R&D Expense | $4.98MM | $3.53MM | $0.06MM |
| Income(Loss) | $-17.35MM | $-23.71MM | $-16.05MM |
| Profit(Loss) | $-17.35MM | $-23.71MM | $-16.05MM |
| Stockholders Equity | $15.77MM | $-2.57MM | $-11.62MM |
| Inventory | $0.00MM | $0.58MM | $2.16MM |
| Assets | $22.41MM | $26.94MM | $26.86MM |
| Operating Cash Flow | $-14.22MM | $-18.06MM | $-17.14MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.00MM |
| Financing Cash Flow | $4.98MM | $20.73MM | $6.64MM |
| Earnings Per Share* | $-0.67 | $-0.95 | $-0.60 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.